C oronary chronic total occlusions (CTOs) are defined as 100% occlusions with TIMI (Thrombolysis in Myocardial Infarction) 0 flow with at least a 3-month duration. 1 Treatment options for patients with coronary CTOs include lifestyle changes and medications (as is appropriate for all patients with coronary artery disease) and coronary revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). In the previous version of the appropriateness use criteria for coronary revascularization, 2 revascularization recommendations were different for patients with and without a coronary CTO, but this is no longer the case in the current (2016 and 2017) versions.
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The goal of this review is to summarize the available evidence on the clinical benefits, likelihood of success, risk for complications, and crossing strategies for CTO PCI and provide practical clinical recommendations.
Clinical Benefits Randomized Trials
The potential benefits of CTO PCI have been and continue to be controversial given the scarcity of randomized controlled trials (Table 1) . [5] [6] [7] [8] [9] [10] Only one randomized controlled trial comparing CTO PCI with medical therapy alone has been published to date, the EXPLORE (Evaluating Xience and Left Ventricular Function in Percutaneous Coronary Intervention on Occlusions After STElevation Myocardial Infarction) trial. 5 The EXPLORE trial randomized 304 patients who underwent primary PCI for STsegment-elevation myocardial infarction (MI) and had a coexisting non-infarct-related artery CTO to CTO PCI versus medical therapy alone. CTO PCI success was 73%. Cardiac magnetic resonance imaging performed after 4 months showed similar left ventricular ejection fraction and left ventricular end-diastolic volume in the 2 study groups. 5 Despite its limitations (enrollment of patients regardless of symptoms and regardless of viability and ischemia of the myocardium supplied by the CTO; potential selection bias given slow enrollment over 7 years at 14 sites; low CTO PCI success rate; and use of a surrogate rather than a clinical primary end point), the EXPLORE trial findings do not support routine PCI of nonculprit CTOs for improving the ejection fraction of patients with recent ST-segment--elevation acute MI. Two other randomized controlled trials were presented in 2017, but neither has been published as of November 2017. The DECISION-CTO (Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients with Chronic Total Occlusion; Clinical Trial Registration-URL: http://www.c linicaltrials.gov. Unique identifier: NCT01078051) trial was presented at the 2017 American College of Cardiology meeting. 6 The EuroCTO (Randomized Multicenter Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions; Clinical Trial Registration-URL: http://www. clinicaltrials.gov. Unique identifier: NCT01760083) was presented at the 2017 EuroPCR meeting. 7 Both trials were stopped before completion of the planned enrollment and were, hence, underpowered. DECISION-CTO trial planned to enroll 1284 patients but was stopped early because of slow enrollment, after randomizing 834 patients with coronary CTOs to CTO PCI or optimal medical therapy alone (OMT). CTO PCI was performed with a high success rate (91%). Concurrent nonocclusive lesions were revascularized in many patients in both groups (77% and 79% for the OMT and CTO PCI groups, respectively). Nearly 20% of the OMT group crossed over to CTO PCI. At 3 years, the primary end point of death, MI, stroke, or repeated revascularization occurred in 19% of the OMT versus 21.4% of high prevalence of non-CTO lesions that were treated after enrollment in both study groups without knowledge of the presence of ischemia or symptoms after non-CTO lesion revascularization; (2) high rates of crossover from OMT to CTO PCI; (3) mild baseline symptoms; (4) suboptimal primary end point, because the main benefit of CTO PCI is expected to be symptom improvement and not improvement in mortality or MI; (5) inappropriate design (noninferiority, although CTO PCI would need to be superior to replace the less invasive OMT); and (6) low power. In contrast to DECISION-CTO trial, QoL was the primary efficacy end point in EuroCTO (Seattle Angina Questionnaire components at 12 months). Patients with non-CTO lesions could not be enrolled until after such lesions were successfully recanalized. The initial plan was to enroll 1200 patients but because of slow enrollment, the study ended after randomizing 407 patients 2:1 to CTO PCI and OMT or OMT alone. Procedural success was 86.3%, and 7.3% of the OMTonly group crossed over to CTO PCI. Likely because of small sample size, the study showed statistically significant improvement with CTO PCI in only 1 of the 5 components of the Seattle Angina Questionnaire (ie, angina frequency; P=0.009).
Although randomized controlled clinical trials are the gold standard for determining the efficacy and safety of an intervention, only 15% of the American College of Cardiology/American Heart Association guideline recommendations are based on level A evidence. 11 
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In summary, large observational studies suggest benefit with CTO recanalization versus medical therapy; however, they are subject to selection and ascertainment bias.
Observational Studies: Impact of CTO PCI on Depression, Exercise Capacity, and Ventricular Arrhythmias Several small observational studies have explored the potential effect of CTO PCI on various surrogate end points, such as depression, exercise capacity, and the risk for ventricular arrhythmias.
Bruckel et al reported a high prevalence of depression among patients with CTOs with significant reduction after successful CTO PCI (40.0% versus 11.1%; P=0.01).
14 Patients who were depressed derived the most benefit from CTO PCI. 14 Rossello et al demonstrated increased 6-minute walking distance (417AE126 m versus 463AE103 m; P=0.002) and decreased angina frequency after successful CTO PCI, especially in patients with a large baseline ischemic burden. 15 Abdullah et al demonstrated increased peak oxygen uptake during cardiopulmonary exercise testing (7.7AE4.3 to 19.1AE4.0 mL/kg per minute; P=0.02) and decreased plasma B-type natriuretic peptide levels (143AE138 to 102AE123 pg/ mL; P=0.01) in 28 patients 5 months after successful CTO PCI. 16 Mashayekhi et al showed improved exercise capacity long-term mortality and the incidence of ventricular arrhythmias in patients with ischemic cardiomyopathy and ICD (n=307) divided into 3 groups: no CTOs (n=94), nonrevascularized CTOs (n=114), and revascularized CTOs (n=99). During a median follow-up of 4.1 years, the 3 groups had similar mortality (P=0.274) and incidence of ventricular arrhythmias (P=0.306). 21 Ischemia testing can facilitate the planning of CTO PCI. Secemsky et al compared the concordance between target vessel selection and ischemic burden (assessed by stress imaging) in patients with CTOs (N=532) who underwent CTO PCI (n=100 [18.8%]) or non-CTO PCI (n=432 [81.2%]). 22 The concordance between target vessel and areas of ischemia was significantly higher in patients who underwent CTO PCI versus those who underwent non-CTO PCI (90.7% versus 67.9%; P<0.0001).
Observational Studies: Successful Versus Failed Procedures
Several studies have compared successful with failed CTO PCI: a meta-analysis of 25 studies compared successful (71%) with failed (29%) CTO PCIs in 28 486 patients. During a mean follow-up of 3.11 years, compared with failed procedures, successful CTO PCI was associated with lower mortality (odds ratio, 0.52), less residual angina (odds ratio, 0.38), lower risk for stroke (odds ratio, 0.72), and less need for subsequent CABG (odds ratio, 0.18).
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The OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) used the Seattle Angina Questionnaire, Rose Dyspnea Scale, and Patient Health Questionnaire in 1000 consecutive patients undergoing CTO PCI using the hybrid approach at 12 experienced US centers. At 1-month follow-up, the Seattle Angina Questionnaire QoL score improved (from 49.4AE0.9 to 75.0AE0.7; P<0.01), with a simultaneous decrease in symptoms of dyspnea (Rose Dyspnea Scale score decreased from 2.0AE0.1 to 1.1AE0.1; P<0.01) and depression (Patient Health Questionnaire score decreased from 6.2AE0.2 to 3.5AE0.1; P<0.01). The most prominent difference in SAQ (Seattle Angina Questionnaire) scores was detected in the QoL domain, with a 10.8 (95% CI, 6.3-15.3) point greater improvement observed in patients with successful versus failed procedures (P<0.001). 8 Comparison of successful versus failed CTO PCIs has important shortcomings, because it is not a randomized comparison and it is likely that patients in whom CTO PCI fails have more complex angiographic characteristics and more comorbidities that can adversely affect subsequent outcomes.
Success of CTO PCI
A meta-analysis of 65 studies published between 2000 and 2011 reported 77% angiographic success and 3.1% risk for MACE. 24 In recent years, several large multicenter registries have reported higher success (%85%-90%) with acceptable complication rates in CTO PCI at various experienced centers and with operators from all around the world, although less optimal results have been reported from all-comer PCI registries (Table 2 ).
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Success of CTO PCI at Experienced Centers
The PROGRESS-CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) reported 91% technical success among 1036 consecutive CTO PCIs performed at 11 US centers. 25 The Japanese Retrograde Summit registry reported 88% success and a remarkably low 0.53% in-hospital complication rate among 3229 CTO PCIs performed at 56 centers in Japan. Higher-volume centers had slightly higher success rates but similar complication rates. 26 The UK Hybrid CTO Registry reported a 90% final technical success rate and a 1.6% 30-day MACE rate among 1156 patients. Compared with low-complexity lesions (J-CTO score, 0-1), more complex lesions (J-CTO score, ≥2) were more likely to require dissection reentry techniques (56% versus 15%) and use of multiple approaches. The technical success rate of the first attempted CTO PCI was 79%, but taking into account repeated procedures, the final success rate increased to 90%. 27 The RECHARGE (Registry of Crossboss and Hybrid Procedures in France, the Netherlands, Belgium, and United Kingdom) reported 89% and 86% technical and procedural success rates, respectively, with a 2.6% incidence of in-hospital major complications among 1253 CTO PCIs performed at 17 European centers by 22 experienced highvolume operators.
The OPEN-CTO Registry reported 86% technical success and 7% incidence of in-hospital MACEs in 1000 consecutive CTO PCIs. 33 The major complication rates were higher than in other studies, mainly related to higher rates of perforation and periprocedural MI (0.9% mortality, 2.6% MI, 0% stroke, 0.7% emergency surgery, and 4.8% clinical perforation). 8 
Success of CTO PCI in All-Comer Registries
The outcomes of CTO PCI in all-comer PCI registries have not been as good as those achieved at experienced centers.
In an analysis from the National Cardiovascular Data Registry in the United States, CTO PCI represented 3.8% of all PCIs for stable coronary artery disease (22 365 of 594 510) performed between 2009 and 2013. CTO PCI was associated with lower success (59% versus 96%; P<0.001) and higher complication (1.6% versus 0.8%; P<0.001) rates, compared with treatment of nonocclusive lesions. Higher CTO PCI volume was associated with higher success (53% for operators performing <5 CTO PCIs/year versus 75% for operators performing >10 CTO PCIs/year; P<0.001) and lower MACE (1.7% versus 1.4%, respectively; P=0.05) rates. 30 Hannan et al 29 
CTO PCI Scores
Several scoring systems have been developed to determine the likelihood of CTO PCI technical success and the potential difficulty of the procedure (measured as time required to cross the occlusion), such as the CL Clinical and lesionrelated) score, 34 Ellis score, 35 Japan-chronic total occlusion score (J-CTO), 36 Ostial, Rentrop grade, Age score (ORA), 37 PROGRESS-CTO score, 38 and RECHARGE score 39 (Table 3) . These scores combine various clinical and angiographic characteristics and can provide a quantitative assessment of the likelihood of success and the difficulty of the case, as long as they are applied in similar settings as the ones that they were developed on. CTO PCI scores may also be useful for scheduling procedures (eg, by avoiding performing multiple high-complexity lesions on the same day). 41 
Bridging the Gap
In summary, the CTO PCI success rates in all-comer registries (54%-80%) are significantly lower than those achieved at experienced centers (85%-90%). Bridging the gap will likely require development of novel equipment and techniques as well as development of comprehensive, high-volume, 42 CTO PCI programs 43 and continued education through live case demonstrations, 44 CTO PCI workshops, and proctorships. 45 CTO PCI is one of the key components of the growing complex, high-risk, PCI programs.
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Complications of CTO PCI
Because of higher lesion and technical complexity, CTO PCI carries a higher risk than non-CTO PCI. In the National Cardiovascular Data Registry, CTO PCI had a 2-fold higher periprocedural complication rate than non-CTO PCI (1.6% versus 0.8%; P<0.0001). 30 Among experienced centers and operators, the contemporary risk of CTO PCI is %3% (Tables 1  and 2 ). A scoring system was recently developed for determining the risk of CTO PCI, the PROGRESS-CTO complication score, which uses 3 variables: age >65 years, lesion length ≥23 mm, and use of the retrograde approach. 48 The estimated procedural risk should be taken into account when decisions are made about proceeding with CTO PCI. Moreover, operators and catheterization laboratories performing CTO PCI should be vigilant and prepared to treat any complications that may arise.
Perforation
Perforation is one of the most feared complications of CTO PCI. Coronary perforations are infrequent (0.33% of all cases) but are associated with poor short-and long-term outcomes. Kinnaird et al analyzed 527 121 interventions of the British Cardiovascular Intervention Society Database, showing that female sex, older age, rotational atherectomy, and CTO PCI were independent predictors of perforation. 49 The incidence of coronary perforations among 26 807 CTO interventions from the same registry was 1.40%. Patients with coronary perforations had a higher incidence of in-hospital and 12-month death, MI, and bleeding requiring transfusion. 50 In another multicenter 
Operator experience + Indicates present; À, absent; BMI, body mass index; CABG, coronary artery bypass grafting; CL, ; CTO, chronic total occlusion; J-CTO, Japan Chronic Total Occlusion score; LAD, left anterior descending artery; LCX, circumflex artery; ORA, ostial location, Rentrop grade <2, age ≥75 years; PCI, percutaneous coronary intervention; PROGRESS-CTO, Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; and RECHARGE, Registry of Crossboss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom. *Moderate tortuosity was defined as 2 bends >70°or 1 bend >90°proximal to the lesion. registry, the incidence of perforation among 2097 CTO PCIs was 4.1%, but only 0.6% required pericardiocentesis. 51 Coronary perforation in patients who underwent prior CABG had been considered less perilous previously, because pericardial adhesions form after sternotomy, potentially preventing tamponade. Recent reports, however, suggest that perforation in patients who underwent prior CABG may result in loculated hematomas, potentially causing localized tamponade and cardiogenic shock. In such cases, computed tomographyguided drainage or surgical intervention may be required to drain the effusion. [52] [53] [54] Intramural bleeding should be suspected if the clinical picture is suggestive of pericardial tamponade, but no pericardial effusion can be detected by echocardiography. 55 Radiation CTO PCI often requires long procedure and fluoroscopy time and may expose both the patient and the operator to high radiation doses that can cause skin injury and increase the subsequent risk for malignancy. Acute dermatitis can develop at the exposed skin area and may progress to chronic skin ulcer if left undiscovered or untreated, occasionally requiring surgical intervention and skin transplantation. 56 Wei et al examined 2124 patients who underwent 2579 PCIs (238 of which were CTO PCIs) and found that a chronic skin ulcer developed in 0.34% (n=9 patients, in 5 of whom the ulcer developed after CTO PCI) and required surgical treatment in 8 patients. 57 The threshold for stopping the procedure because of high radiation exposure is 7 to 10 Gy air kerma dose, and postprocedural monitoring and referral for dermatologist follow-up are recommended for air kerma doses >5 Gy. In part because of an increase in popularity of CTO PCI and increasing emphasis on procedural safety, there have been significant reductions in patient radiation dose over time, by using low fluoroscopy rates (6-7.5 frames per second), newer x-ray systems that administer a lower radiation dose, 58 and better radiation safety techniques. 59 Werner et al 60 examined
984 CTO PCIs performed in 863 patients between 2010 and 2015. During that period, fluoroscopy settings were changed (15 to 7.5 and then to 6 pulses/second), with a cine frame rate of 15 to 7.5/second. Despite an increase in lesion complexity and similar fluoroscopy times, dose area product significantly decreased during the study period (initially by 20%, followed by an additional 7% reduction). 60 Additional shielding (eg, using disposable sterile radiation shields) could further reduce operator radiation dose. 61 
CTO PCI Techniques
The most challenging portion of most CTO PCIs is crossing the occlusion with a guidewire. There are 3 main crossing techniques: antegrade wire escalation (AWE), antegrade dissection/reentry, and the retrograde approach.
Antegrade Wire Escalation
AWE (ie, sequential use of various guidewires in the antegrade direction, from the proximal to the distal part of the vessel) is the most commonly used initial and final CTO crossing technique (66%-78%), [25] [26] [27] [28] especially for less complex occlusions. 62 
Antegrade Dissection and Reentry
Antegrade dissection and reentry (ADR) refers to use of the subintimal (or subadventitial) space for crossing the occlusion, followed by reentry into the distal true lumen using guidewires or dedicated systems, such as the Stingray balloon and guidewire (Boston Scientific, Natick, MA). [63] [64] [65] [66] [67] The early version of these techniques created extensive areas of dissection and was associated with suboptimal short-and long-term outcomes 68 ; hence, limited dissection techniques (minimizing the length of dissection and consequent side branch loss) are preferred. 64 Danek et al 69 
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As part of RECHARGE, Maeremans et al 70 analyzed the outcomes and safety of the antegrade dissection reentry in 292 patients. ADR techniques overall were used for complex lesions (J-CTO score, 2.7AE1.1), with 78% per-lesion success rate and 3.1% complication rate. 70 Azzalini et al compared the long-term outcomes of CTO PCIs using device-based antegrade dissection reentry strategies (CrossBoss/Stingray [Boston Scientific]) with wire-based dissection reentry techniques (subintimal tracking and reentry and limited antegrade subintimal tracking) in a multicenter registry of 223 cases. 71 When comparing device-based reentry with subintimal tracking and reenty (STAR) and limited antegrade subintimal tracking, the device-based reentry strategies (ie, CrossBoss/Stingray) had significantly lower incidence of MACE (4.3% versus 15.4% and 17.5%; P=0.02) and target vessel revascularization (3.1% versus 7.7% and 15.5%; P=0.02).
Hasegawa et al 72 compared the midterm outcomes of intimal with subintimal tracking by using both antegrade and retrograde crossing. Subintimal tracking occurred less frequently in the antegrade group (11.6% versus 30.9%; P<0.01), requiring target vessel revascularization more frequently in the retrograde group (7.1% versus 16.0%; P=0.03) but not in the antegrade group (2.8% versus 3.6%; P=0.99). 72 Song et al 73 compared intraplaque with subintimal wire crossing using intravascular ultrasonographic assessment for acute vessel damage and complications. Subintimal tracking was more common with dissection reentry strategies than with wire escalation (86.7% versus 27.9%) in more complex lesions (J-CTO score: 2.5AE1.1 versus 1.6AE1.1; P<0.001).
Subintimal crossing was associated with a higher composite of in-hospital all-cause death, periprocedural MI, and target lesion revascularization (7.9% versus 1.9%; P=0.04), driven by periprocedural MI (7.0% versus 1.9%; P=0.1). Subintimal tracking was associated with a higher rate of intravascular ultrasound-detected vascular injury (89.5% versus 52.4%; P<0.001), angiographic dye staining/extravasation (14.0% versus 3.8%; P=0.01), and branch occlusion (48.2% versus 16.2%; P<0.001).
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In summary, limited ADR techniques are a key component of contemporary CTO PCI, especially for crossing complex CTOs, and are associated with favorable short-and long-term outcomes.
Retrograde Approach
The retrograde approach involves advancement of a guidewire through a collateral vessel or bypass grafts into the distal true lumen, followed by CTO crossing against the former direction of blood flow. Similar to ADR, the retrograde approach is an essential tool for achieving high CTO PCI success rates, [74] [75] [76] especially in more complex cases and when antegrade crossing strategies are not feasible or fail to achieve crossing. 25, 27 However, the retrograde approach carries higher risk for procedure-related complications. Results of the largest retrograde CTO PCI registries (>300 cases) published to date are summarized in Table 4 . [74] [75] [76] [77] [78] Careful selection of collateral channels is essential for optimizing the success and safety of the retrograde approach. Various pathways (septal and epicardial collaterals, saphenous vein grafts, and arterial grafts) can be used for retrograde crossing.
The European CTO Club reported 75.3% technical and 71.2% clinical success among 1582 retrograde CTO PCIs, with significant improvement over time (73.5%, 65.8%, 73.0%, 74.7%, and 79.2%, between 2008 and 2012). The overall procedural complication rate was 6.8%, whereas the inhospital major adverse cardiac and cerebrovascular event (defined as any cardiac death, stroke, and repeated revascularization during the hospital stay) rate was 0.8%. During a mean follow-up of 24.7 months, all-cause mortality rate was 3.9%, cardiac mortality rate was 1.9%, and overall major adverse cardiac and cerebrovascular event rate was 13.6%. 77 Karmpaliotis et al 78 with coils, fat, or thrombin. 84 Use of epicardial collaterals is usually reserved for highly experienced operators and centers ( Figure 1 ). 85 In summary, retrograde is an important CTO PCI technique but should be used with caution, because it carries increased risk for complications, especially through epicardial collaterals and in patients who underwent prior CABG.
Selection of Crossing Technique
Determining the optimal initial and subsequent crossing strategy depends on the angiographic characteristics of the lesion and should be selected after detailed review of the angiogram. The hybrid approach (Figure 2 ) starts with dual angiography and focuses on assessment of 4 anatomic features (proximal cap ambiguity, distal target vessel, interventional collateral, and lesion length), recommending early change if the initially selected strategy is not successful. 33 Another algorithm is the Asia Pacific algorithm (http://apc to.club/apcto-algorithm), which is also based on the CTO anatomic characteristics and gives preference to parallel wiring and intravascular ultrasound-guided wiring 86 over antegrade dissection and reentry, reflecting the local expertise in the countries where it was developed.
40,87
Remaining Controversies
Randomized Controlled Trials
As described earlier, only 3 randomized controlled clinical trials comparing CTO PCI with medical therapy have been performed to date, the EXPLORE, DECISION-CTO, and EuroCTO trials. Of the 3 trials, 2 (the DECISION-CTO and EuroCTO trials) were stopped prematurely before completion of planned enrollment and were, thus, underpowered. Moreover, DECISION-CTO trial randomized several patients with multivessel coronary artery disease before revascularization of the non-CTO lesions, limiting assessment of the impact of CTO PCI. Given the potential placebo effect of CTO PCI on QoL, there is a need for a well-designed and adequately powered sham-controlled, randomized clinical trial to definitively answer the question of the impact of CTO PCI on patient symptoms.
Use of Dissection/Reentry Strategies
There is ongoing controversy on the use and timing of dissection/reentry (both antegrade and retrograde) techniques in contemporary CTO PCI. As described in the Antegrade Dissection and Reentry section, extensive dissection/reentry has been associated with a high risk for periprocedural complications (eg, periprocedural MI) and high rates of restenosis, likely because of side branch loss, and is only used as a bailout. The CrossBoss First trial compared upfront use of the CrossBoss catheter with AWE for CTO crossing. 88 It demonstrated similar crossing time, success and complication rates, and costs, suggesting that both strategies are acceptable as an initial approach. Crossing time was shorter with upfront use of the CrossBoss catheter in in-stent restenotic lesions. Antegrade dissection/reentry was the final successful strategy in 22% of the AWE group, demonstrating the importance of these techniques at various stages of contemporary CTO PCI. Additional studies comparing various crossing strategies are important for further optimizing the initial and subsequent strategy selection for CTO PCI.
Radial Versus Femoral Approach in CTO PCI
Access site selection is important in CTO PCI for providing appropriate support and allowing enough space for multiple devices during various techniques. Eight French guiding catheters, via transfemoral access, are often recommended, because they provide strong support, but may carry a higher risk for vascular complications. 89 Access with ultrasound and fluoroscopic guidance could reduce the risk for arterial access complications. 90 Murakami et al showed that transradial CTO PCI can be effective in appropriately selected cases 91 ; however, bifemoral access was used for more complex cases. 92 Alaswad et al demonstrated that CTO PCI using at least one transradial access was feasible, with high success rates, but at the cost of longer fluoroscopy and mean procedure time. 93 The 8F sheathless guide catheters 94 or 7F slender sheaths (Terumo, Somerset, NJ) are increasingly being used for radial CTO PCI and may facilitate wider adoption of the radial approach for CTO (and other complex) PCIs.
Conclusions
All decisions in medicine should be based on the risk/benefit ratio ( Figure 3) . The main and best documented to date benefit of CTO PCI is symptom improvement (ie, improvement in angina or angina equivalents). Consequently, for truly asymptomatic patients, there should be a high threshold for doing CTO PCI for other indications, such as ischemia reduction or improvement in ejection fraction. Deriving benefit requires successful recanalization; hence, estimating the likelihood of success (85%-90% at experienced centers) is critical for accurate estimation of the potential benefit. The risk of major procedural complications is %3% and depends on patient age, lesion complexity, and crossing techniques used. Use of scoring systems can be useful for providing the patient and operator with an objective assessment of the likelihood of success and procedural risk, provided that the scores are used by operators and patients similar to those from whom the scores were derived. Successful CTO PCI in appropriately selected patients can provide significant clinical benefits and improve their QoL. 
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